title: Evaluation of an algorithm for intensive subcutaneous insulin therapy in noncritically ill hospitalised patients with hyperglycaemia in a randomised controlled trial.
abstract: BACKGROUND
  Currently glycaemic targets of <7.8 mmol/l without hypoglycaemia are recommended for diabetic patients on general wards before meals. Efficient and safe strategies to achieve these targets with subcutaneous insulin injections outside the intensive care setting are not well established. The aim of this trial was to evaluate a subcutaneous insulin algorithm, which incorporates insulin resistance due to individual features and acute illness, for correction of hyperglycaemia in general medical wards.
  
  
  METHODS
  This was a two-centre, randomised controlled trial in two Swiss hospitals. Patients with initial plasma glucose levels >8 mmol/l were randomised to either an intervention group or a control group. The primary endpoint was the time in the glycaemic target range (5.5-7.0 mmol/l) within the first 48 hours.
  
  
  RESULTS
  Patients in the intervention group (n = 67) had significantly lower plasma glucose levels during the first 48 hours as compared with control patients (n = 63) (7.7 ± 3.0 mmol/l; mean ± standard deviation [SD]) vs 9.7 ± 3.9 mmol/l, p <0.0001). The intervention group reached the glycaemic target range earlier (median 9.5 vs 24.0 hours, p <0.0001) and remained longer in this range (difference: 9.5 hours, 95% confidence interval [CI] 5.1, 13.9). There were more episodes of mild hypoglycaemia in the intervention group (19.4% vs 6.3%, absolute difference 13.5%, 95%CI 1.8, 24.3), with no difference in rates of severe hypoglycaemia.
  
  
  CONCLUSIONS
  Incorporation of insulin resistance factors into a subcutaneous insulin algorithm achieved early and sustained glycaemic control in noncritically ill patients admitted to general medical wards without apparent safety concerns. The overall clinical benefit of this strategy remains to be determined.
authors.affiliation: Internal Medicine, Bürgerspital Solothurn, Switzerland. roebithomann@bluewin.ch
authors.forename: R
authors.initials: R
authors.lastname: Thomann
authors.forename: P
authors.initials: P
authors.lastname: Schütz
authors.forename: B
authors.initials: B
authors.lastname: Müller
authors.forename: S
authors.initials: S
authors.lastname: Thomke
authors.forename: R
authors.initials: R
authors.lastname: Schoenenberger
authors.forename: U
authors.initials: U
authors.lastname: Keller
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D005240:Feasibility Studies; D005260:Female; D006760:Hospitalization; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy* / Q000209:etiology; D007003:Hypoglycemia / Q000139:chemically induced; D007279:Injections, Subcutaneous; D007328:Insulin / Q000627:therapeutic use*; D007333:Insulin Resistance; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D007328:Insulin